Research programme: SSAO/VAP-1 protein inhibitors - PharmaxisAlternative Names: PXS4159; PXS4206
Latest Information Update: 30 May 2015
At a glance
- Originator Pharmaxis
- Class Small molecules
- Mechanism of Action AOC3 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma